c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 143 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Formula:C27H23FN4O4SPurity:99.39%Color and Shape:SolidMolecular weight:518.56Ref: TM-T13108
1mg52.00€5mg101.00€10mg149.00€25mg244.00€50mg359.00€100mg510.00€200mg695.00€1mL*10mM (DMSO)127.00€Emibetuzumab
CAS:Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Purity:SDS-PAGE:96.2%;SEC-HPLC:98.8%Color and Shape:LiquidMolecular weight:143.74 kDaRilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.
Purity:SDS-PAGE:95% SEC-HPLC:97.51%Color and Shape:LiquidMolecular weight:145.2 kDaSU 5616
CAS:SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.
Formula:C13H8ClNOSPurity:98.84%Color and Shape:SoildMolecular weight:261.73Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formula:C20H15F3N8Purity:99.16%Color and Shape:SolidMolecular weight:424.38Ref: TM-T10585
1mg92.00€5mg205.00€10mg334.00€25mg595.00€50mg858.00€100mg1,198.00€200mg1,611.00€1mL*10mM (DMSO)227.00€CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Formula:C20H20FN7O2Purity:99.29%Color and Shape:SolidMolecular weight:409.42JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Formula:C20H12F2N6Purity:98.84% - 99.74%Color and Shape:SolidMolecular weight:374.35Ref: TM-T15617
1mg59.00€5mg130.00€10mg200.00€25mg401.00€50mg557.00€100mg737.00€1mL*10mM (DMSO)144.00€Onartuzumab
CAS:Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Purity:97.3%Color and Shape:LiquidMolecular weight:146.99 kDac-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Formula:C17H14N8SPurity:98.77%Color and Shape:SolidMolecular weight:362.41C-Met inhibitor D9
CAS:C-Met inhibitor D9 is a c-Met kinase inhibitor.Formula:C17H15N3O2Purity:97.45%Color and Shape:SolidMolecular weight:293.32PROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Formula:C51H50F2N6O13Color and Shape:SolidMolecular weight:992.97PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formula:C51H54N10O7Color and Shape:SolidMolecular weight:919.037PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formula:C25H22N8O5SPurity:98%Color and Shape:SolidMolecular weight:546.56PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Formula:C45H41FN10O5Color and Shape:SolidMolecular weight:820.87c-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Color and Shape:Odour SolidLMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formula:C18H11F3N4OPurity:99.58%Color and Shape:SoildMolecular weight:356.3Norleual
CAS:Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.
Formula:C41H58N8O7Purity:98%Color and Shape:SolidMolecular weight:774.95c-Met-IN-19
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,Formula:C34H37Cl2FN4O7SPurity:98%Color and Shape:SolidMolecular weight:735.65Narnatumab
CAS:Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.Purity:>95%Color and Shape:LiquidMolecular weight:145.8 kDaUmikibart
Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.Color and Shape:Odour LiquidFosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formula:C29H49N4O10PPurity:98.01%Color and Shape:SolidMolecular weight:644.69Ref: TM-T39507L
1mg116.00€2mg160.00€5mg238.00€10mg353.00€25mg563.00€50mg758.00€100mg1,017.00€200mg1,359.00€CE-355621
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37Telisotuzumab
CAS:Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.
Purity:SDS-PAGE:96.4%;SEC-HPLC:98.5%Color and Shape:LiquidMolecular weight:145.50 kDa1D228
1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration ofPurity:98%Color and Shape:Odour SolidCaveolin-1 (82-101) amide (human, mouse, rat)
CAS:Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFormula:C124H170N28O29Purity:98%Color and Shape:SolidMolecular weight:2516.85BMS-777607
CAS:BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Formula:C25H19ClF2N4O4Purity:98.16% - 98.56%Color and Shape:SolidMolecular weight:512.89Ref: TM-T2658
2mg59.00€5mg86.00€10mg135.00€25mg251.00€50mg388.00€100mg690.00€200mg1,034.00€500mg1,550.00€c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Formula:C21H15FN4O2Purity:98%Color and Shape:SolidMolecular weight:374.37Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Formula:C34H29ClF2N6O5Purity:98%Color and Shape:SolidMolecular weight:675.08c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Formula:C16H13N7OMolecular weight:319.11816SYN1143
CAS:SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Formula:C31H29FN4O5Purity:99.69%Color and Shape:SolidMolecular weight:556.58PF-04217903 methanesulfonate
CAS:PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formula:C20H20N8O4SPurity:98%Color and Shape:SolidMolecular weight:468.49Norleual TFA
Norleual TFA, Ang IV analog, inhibits HGF/c-Met (IC50: 3 pM), blocks AT4, and has strong antiangiogenic effects.Formula:C43H59F3N8O9Molecular weight:888.97S49076 HCl
CAS:S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Formula:C22H18ClN3O5Purity:98%Color and Shape:SolidMolecular weight:439.85SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Formula:C25H23FN8O2S2·HClPurity:97.95%Color and Shape:SolidMolecular weight:587Ref: TM-T5677
1mg35.00€5mg57.00€10mg95.00€25mg178.00€50mg264.00€100mg374.00€200mg537.00€1mL*10mM (DMSO)96.00€NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Formula:C31H23F2N5O3Purity:98.48%Color and Shape:SolidMolecular weight:551.54Ref: TM-T6907
1mg34.00€2mg46.00€5mg66.00€10mg92.00€25mg167.00€50mg245.00€100mg356.00€200mg530.00€1mL*10mM (DMSO)82.00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Formula:C19H16N8OPurity:98.41% - 98.55%Color and Shape:SolidMolecular weight:372.38CEP-40783
CAS:CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
Formula:C31H26F2N4O6Purity:99.76% - 99.84%Color and Shape:SolidMolecular weight:588.56Ningetinib Tosylate
CAS:Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C38H37FN4O8SPurity:99.93%Color and Shape:SolidMolecular weight:728.79Crizotinib
CAS:Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Formula:C21H22Cl2FN5OPurity:99% - 99.87%Color and Shape:SolidMolecular weight:450.34Ref: TM-T1661
2mgTo inquire5mg33.00€10mg49.00€25mg55.00€50mg64.00€100mg88.00€500mg147.00€1mL*10mM (DMSO)50.00€AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formula:C22H17N5O2Purity:98.56%Color and Shape:SolidMolecular weight:383.4S49076
CAS:S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Formula:C22H22N4O4SPurity:95.35% - 97.4%Color and Shape:SolidMolecular weight:438.5Ref: TM-T3274
1mg34.00€2mg44.00€5mg58.00€10mg93.00€25mg167.00€50mg260.00€100mg432.00€200mg618.00€1mL*10mM (DMSO)64.00€DS-1205
CAS:DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Formula:C41H42FN5O7Purity:99.75%Color and Shape:SolidMolecular weight:735.8Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Formula:C23H19Cl2FN6OPurity:98.80%Color and Shape:SolidMolecular weight:485.34Ref: TM-T4260
2mg34.00€5mg49.00€10mg64.00€25mg84.00€50mg92.00€100mg126.00€500mg303.00€1mL*10mM (DMSO)58.00€SGX-523
CAS:SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
Formula:C18H13N7SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:359.41PHA-665752
CAS:PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Formula:C32H34Cl2N4O4SPurity:97.05% - 98.82%Color and Shape:SolidMolecular weight:641.61Amuvatinib
CAS:Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.Formula:C23H21N5O3SPurity:99.38% - >99.99%Color and Shape:SolidMolecular weight:447.51BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Formula:C23H15ClF2N4O3Purity:98% - 99.69%Color and Shape:SolidMolecular weight:468.84Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H17FN6OPurity:99.24%Color and Shape:SolidMolecular weight:412.42Ref: TM-T1963
5mg48.00€10mg63.00€25mg78.00€50mg90.00€100mg124.00€200mg158.00€500mg255.00€1mL*10mM (DMSO)50.00€Afatinib Dimaleate
CAS:Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Formula:C32H33ClFN5O11Purity:98.11% - 99.87%Color and Shape:SolidMolecular weight:718.08c-Kit-IN-1
CAS:c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).Formula:C26H21F2N5O3Purity:98.72% - 98.73%Color and Shape:SolidMolecular weight:489.47Ref: TM-T4332
1mg39.00€5mg81.00€10mg120.00€25mg235.00€50mg373.00€100mg610.00€200mg840.00€1mL*10mM (DMSO)88.00€X-376
CAS:X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.Formula:C25H25Cl2FN6O3Purity:97.87%Color and Shape:SolidMolecular weight:547.41Ref: TM-T3550
1mg35.00€2mg50.00€5mg87.00€10mg119.00€25mg258.00€50mg427.00€100mg582.00€1mL*10mM (DMSO)105.00€BMS817378
CAS:BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Formula:C24H18ClF2N4O7PPurity:>99.99%Color and Shape:SolidMolecular weight:578.85Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFormula:C26H29Cl4FN6O3Purity:98.73%Color and Shape:SolidMolecular weight:634.36Ref: TM-T22324
1mg54.00€5mg114.00€10mg177.00€25mg356.00€50mg580.00€100mg888.00€1mL*10mM (DMSO)158.00€Glumetinib
CAS:Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).
Formula:C21H17N9O2SPurity:99.79%Color and Shape:SolidMolecular weight:459.48Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Formula:C17H13BrN2Purity:97.67%Color and Shape:SolidMolecular weight:325.2Ref: TM-T25492
1mg35.00€2mg52.00€5mg80.00€10mg119.00€25mg231.00€50mg344.00€100mg480.00€200mg663.00€1mL*10mM (DMSO)92.00€Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.46NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formula:C20H16N6Purity:97.24% - >99.99%Color and Shape:SolidMolecular weight:340.38Ref: TM-T2680
2mg44.00€5mg74.00€10mg97.00€25mg178.00€50mg255.00€100mg359.00€200mg510.00€1mL*10mM (DMSO)84.00€BMS 777607
CAS:BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Formula:C25H19ClF2N4O4Purity:98.89% - >99.99%Color and Shape:SolidMolecular weight:512.89Ref: TM-T2699
1mg35.00€5mg79.00€10mg124.00€25mg217.00€50mg359.00€100mg533.00€500mg1,169.00€1mL*10mM (DMSO)92.00€MK-8033
CAS:MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Formula:C25H21N5O3SPurity:97.16%Color and Shape:SolidMolecular weight:471.53Golvatinib
CAS:Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFormula:C33H37F2N7O4Purity:98.24% - ≥95%Color and Shape:SolidMolecular weight:633.69Ref: TM-T6517
1mgTo inquire2mg46.00€5mg66.00€10mg92.00€25mg149.00€50mg197.00€100mg350.00€1mL*10mM (DMSO)To inquireAMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Formula:C23H22FN7O3Purity:99.26% - 99.9%Color and Shape:SolidMolecular weight:463.46Ref: TM-T3209
1mg40.00€2mg52.00€5mg85.00€10mg124.00€25mg197.00€50mg350.00€100mg522.00€200mg748.00€1mL*10mM (DMSO)86.00€Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H21Cl2FN6O2Purity:99.77%Color and Shape:SolidMolecular weight:503.36Ref: TM-T8825
2mg34.00€5mg48.00€10mg63.00€25mg84.00€50mg92.00€100mg126.00€500mg250.00€1mL*10mM (DMSO)50.00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formula:C34H34F2N4O6Purity:98.07% - 99.68%Color and Shape:SolidMolecular weight:632.65Ref: TM-T3113
2mg39.00€5mg57.00€10mg79.00€25mg133.00€50mg207.00€100mg354.00€500mg848.00€1mL*10mM (DMSO)79.00€Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C31H29FN4O5Purity:99.95% - 99.98%Color and Shape:SolidMolecular weight:556.58Afatinib
CAS:Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.
Formula:C24H25ClFN5O3Purity:98.56% - 99.9%Color and Shape:Off-White SolidMolecular weight:485.94BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFormula:C17H15N5Purity:98.98%Color and Shape:SolidMolecular weight:289.33Ref: TM-T7900
1mg35.00€5mg71.00€10mg112.00€25mg203.00€50mg294.00€100mg411.00€200mg553.00€1mL*10mM (DMSO)84.00€Crizotinib hydrochloride
CAS:Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Formula:C21H23Cl3FN5OPurity:98.73% - 98.87%Color and Shape:SolidMolecular weight:486.8Ref: TM-T8399
5mg34.00€10mg50.00€25mg78.00€50mg94.00€100mg131.00€200mg162.00€500mg215.00€1mL*10mM (DMSO)56.00€Cabozantinib hydrochloride
CAS:Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Formula:C28H25ClFN3O5Purity:99.97%Color and Shape:SolidMolecular weight:537.96Ref: TM-T5164
1mg42.00€2mg52.00€5mg65.00€10mg92.00€25mg160.00€50mg235.00€100mg330.00€200mg538.00€500mg860.00€(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFormula:C15H14N2OPurity:98.82% - ≥95%Color and Shape:SolidMolecular weight:238.28Ref: TM-T2496
10mg35.00€25mg52.00€50mg79.00€100mg111.00€200mg168.00€500mg330.00€1mL*10mM (DMSO)44.00€Cabozantinib
CAS:Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).
Formula:C28H24FN3O5Purity:99.68% - 99.88%Color and Shape:SolidMolecular weight:501.51SRI 31215 TFA
CAS:SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Formula:C27H34F3N5O3Purity:98.25% - 99.97%Color and Shape:SolidMolecular weight:533.6Ref: TM-T5478
1mg40.00€5mg92.00€10mg128.00€25mg248.00€50mg370.00€100mg527.00€200mg713.00€1mL*10mM (DMSO)96.00€Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Formula:C23H18ClFN6OPurity:98.62% - 99.81%Color and Shape:SolidMolecular weight:448.89Merestinib dihydrochloride
CAS:Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.Formula:C30H24Cl2F2N6O3Color and Shape:SolidMolecular weight:625.45Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Formula:C17H15N9Purity:98.12%Color and Shape:SolidMolecular weight:345.36Ref: TM-TQ0210
1mg47.00€2mg60.00€5mg96.00€10mg124.00€25mg200.00€50mg353.00€100mg537.00€1mL*10mM (DMSO)92.00€MGCD-265 analog
CAS:Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Formula:C26H20FN5O2S2Purity:98.06% - 98.68%Color and Shape:SolidMolecular weight:517.6Merestinib
CAS:Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Formula:C30H22F2N6O3Purity:95% - 99.71%Color and Shape:SolidMolecular weight:552.53Ref: TM-T3455
1mg50.00€2mg66.00€5mg100.00€10mg137.00€25mg240.00€50mg403.00€100mg573.00€500mg1,198.00€1mL*10mM (DMSO)119.00€Tivantinib
CAS:Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Formula:C23H19N3O2Purity:98% - 99.41%Color and Shape:SolidMolecular weight:369.42RPI-1
CAS:RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.Formula:C17H15NO4Purity:98.91% - ≥95%Color and Shape:SolidMolecular weight:297.31SGI-7079
CAS:SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.Formula:C26H26FN7Purity:95.51% - 99.26%Color and Shape:SolidMolecular weight:455.53Ref: TM-T6982
2mg39.00€5mg58.00€10mg92.00€25mg178.00€50mg230.00€100mg334.00€500mg782.00€1mL*10mM (DMSO)64.00€JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Formula:C19H13F2N7Purity:97.15% - 98.61%Color and Shape:SolidMolecular weight:377.35BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Formula:C25H16F2N4O3Purity:98.33%Color and Shape:SolidMolecular weight:458.42Ref: TM-T8326
1mg67.00€2mg88.00€5mg148.00€10mg230.00€25mg430.00€50mg622.00€100mg898.00€1mL*10mM (DMSO)170.00€XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Formula:C29H25FN4O5Purity:98.60%Color and Shape:SolidMolecular weight:528.53SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFormula:C32H40ClF2N6O13PPurity:98.07%Color and Shape:SolidMolecular weight:821.12Ref: TM-T5349
1mg35.00€2mg50.00€5mg74.00€10mg113.00€25mg200.00€50mg333.00€100mg495.00€1mL*10mM (DMSO)102.00€Pamufetinib mesylate
CAS:Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Formula:C28H27FN4O7S2Purity:98.91%Color and Shape:SolidMolecular weight:614.67Foretinib phosphate
CAS:Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Formula:C34H40F2N4O14P2Color and Shape:SolidMolecular weight:828.65Amivantamab (Anti-c-MET)
CAS:Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.Purity:97.24% (SEC-HPLC) - >95.0% (SDS-PAGE); 99.74% (SEC-HPLC)Color and Shape:LiquidMolecular weight:145.88 kDaDavutamig
CAS:Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Purity:98%Color and Shape:LiquidBafisontamab
CAS:Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Color and Shape:LiquidMAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFormula:C20H11Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:380.23BMS-754807
CAS:BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Formula:C23H24FN9OPurity:99.69% - 99.94%Color and Shape:SolidMolecular weight:461.49Ref: TM-T2349
1mg50.00€2mg66.00€5mg90.00€10mg158.00€25mg310.00€50mg509.00€100mg732.00€1mL*10mM (DMSO)110.00€SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Formula:C28H30ClN5O4SPurity:98.62% - 99.53%Color and Shape:Orange PowderMolecular weight:568.09Ref: TM-T6154
1mg44.00€2mg56.00€5mg92.00€10mg142.00€25mg268.00€50mg442.00€100mg652.00€1mL*10mM (DMSO)142.00€AMG-458
CAS:AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Formula:C30H29N5O5Purity:99.91% - 99.98%Color and Shape:SolidMolecular weight:539.58Glesatinib hydrochloride
CAS:Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Formula:C31H28ClF2N5O3S2Purity:98%Color and Shape:SolidMolecular weight:656.16Glesatinib
CAS:Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Formula:C31H27F2N5O3S2Purity:98%Color and Shape:SolidMolecular weight:619.7AC-386
CAS:AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.Formula:C35H34FN5O6Color and Shape:SolidMolecular weight:639.67LCRF-0004
CAS:LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.Formula:C28H18F4N6O2SColor and Shape:SolidMolecular weight:578.54c-Met-IN-11
CAS:c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).Formula:C30H20F2N4O3Color and Shape:SolidMolecular weight:522.5Axl-IN-8
CAS:Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).Formula:C31H29FN6O3Color and Shape:SolidMolecular weight:552.6Mifanertinib
CAS:Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .Formula:C21H19ClF3N5O2Color and Shape:SolidMolecular weight:465.86
